We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Suggests Vioxx Heart Risks Unique; Merck Sees Cox-2 Class Effect
Pfizer Suggests Vioxx Heart Risks Unique; Merck Sees Cox-2 Class Effect
February 16, 2005
Two drug giants squared off yesterday over the question of whether the increased cardiovascular (CV) risks associated with Cox-2 inhibitor drugs are unique to certain products or are found across the entire class of pain treatments.